KOREA WHO
-
-
-
CEO of LigaChem Biosciences
Kim Yong-zu
Pioneer in Antibody-Drug Conjugates (ADC), Advances Drug Development Under Orion Group
-
Last Updated on Jan 8, 2025
-
CEO of LigaChem Biosciences
Life Summary
Kim Yong-zu is the CEO of LigaChem Biosciences.
He was born on May 17, 1956, in Daejeon.
He graduated from Daejeon High School and the Department of Chemistry at Seoul National University. He earned a master’s degree and a doctorate in organic chemistry from the Korea Advanced Institute of Science and Technology (KAIST).
After serving as the director of the LG Chem Technology Research Institute, he worked as the head of the U.S. branch of LG Life Sciences and as the director of the New Drug Research Institute at the Technology Research Institute.
In 2006, he founded LegoChem Biosciences (now LigaChem Biosciences), which focuses on pharmaceutical research and development.
He transferred the position of the largest shareholder to Orion Group and is currently leading the company as the second-largest shareholder.
He has focused on the field of Antibody-Drug Conjugates (ADC), a targeted cancer therapy, and aims to establish the company as a new drug development enterprise that conducts its own clinical trials.
#KimYongzu #LigaChemBiosciences #biotechnology #pharmaceuticals #organicchemistry #newdrugdevelopment #antibodydrugconjugates #cancertherapy #OrionGroup #biopharma
He was born on May 17, 1956, in Daejeon.
He graduated from Daejeon High School and the Department of Chemistry at Seoul National University. He earned a master’s degree and a doctorate in organic chemistry from the Korea Advanced Institute of Science and Technology (KAIST).
After serving as the director of the LG Chem Technology Research Institute, he worked as the head of the U.S. branch of LG Life Sciences and as the director of the New Drug Research Institute at the Technology Research Institute.
In 2006, he founded LegoChem Biosciences (now LigaChem Biosciences), which focuses on pharmaceutical research and development.
He transferred the position of the largest shareholder to Orion Group and is currently leading the company as the second-largest shareholder.
He has focused on the field of Antibody-Drug Conjugates (ADC), a targeted cancer therapy, and aims to establish the company as a new drug development enterprise that conducts its own clinical trials.
#KimYongzu #LigaChemBiosciences #biotechnology #pharmaceuticals #organicchemistry #newdrugdevelopment #antibodydrugconjugates #cancertherapy #OrionGroup #biopharma